• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    10/21/24 4:18:16 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    SC 13G 1 zenasbiopharmainc-xencorsc.htm SC 13G Document

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
    Zenas BioPharma, Inc.
    (Name of Issuer)
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    98937L105
    (CUSIP Number)
    September 16, 2024
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. 98937L105
     
      1   
      NAMES OF REPORTING PERSONS
     Xencor, Inc.
      2 
      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)  ☐        (b)  ☒
     
      3 
      SEC USE ONLY
     
      4 
      CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
    NUMBER OF
    SHARES
     BENEFICIALLY 
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
      5    
      SOLE VOTING POWER
     
      3,098,380
      6  
      SHARED VOTING POWER
     
      0
      7  
      SOLE DISPOSITIVE POWER
     
      3,098,380
      8  
      SHARED DISPOSITIVE POWER
     
      0
      9   
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      3,098,380
    10 
      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
      ☐
    11 
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
      7.4%(1)
    12 
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
      CO

    (1)     This percentage is calculated based upon 41,777,675 shares of the Issuer’s Common Stock outstanding after Issuer's initial public offering ("IPO") as reported in the Issuer's prospectus dated September 12, 2024 filed with the Securities and Exchange Commission on September 13, 2024 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.








    Item 1(a).    Name of Issuer:
    Zenas BioPharma, Inc.
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
    1000 Winter Street, North Building, Suite 1200
    Waltham, MA 02451
    Item 2(a).    Name of Person Filing:
    Xencor, Inc.
    (the “Reporting Person”)
    Item 2(b).    Address of Principal Business Office or, if none, Residence:
    The address of the principal business office of the Reporting Person is:
    465 N. Halstead St. Suite 200
    Pasadena, California 91107
    Item 2(c).    Citizenship:
    The Reporting Person is a corporation organized under the laws of the State of Delaware.
    Item 2(d).    Title of Class of Securities:
    Common Stock, par value $0.0001 per share (“Common Stock”)
    Item 2(e).    CUSIP Number:
    98937L105
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable
    Item 4.    Ownership

    The Reporting Person directly holds 3,098,380 shares of Common Stock. The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G.
    Item 5.    Ownership of 5 Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
    Item 6.    Ownership of More than 5 Percent on Behalf of Another Person:
    Not applicable
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:
    Not applicable
    Item 8.    Identification and Classification of Members of the Group:
    Not applicable
    Item 9.    Notice of Dissolution of a Group:
    Not applicable
    Item 10.    Certifications:
    Not applicable



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: October 21, 2024
    XENCOR, INC.

    By:
    /s/ Celia Eckert
    Celia Eckert
    General Counsel & Corporate Secretary


    ATTENTION:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)



    Get the next $ZBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$27.00Buy
    Citigroup
    More analyst ratings

    $ZBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

    SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/8/25 11:46:16 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

    9/2/25 7:15:16 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Zenas BioPharma Inc.

    S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

    8/12/25 8:02:03 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

    WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference on Tuesday, September 2, 2025, at 1:00 p.m. ETCantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 8:35 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET Live webcasts and archived

    8/26/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Zenas Biopharma with a new price target

    Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

    3/20/25 8:00:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Zenas Biopharma with a new price target

    Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

    2/4/25 7:13:29 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

    H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

    12/16/24 6:47:20 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

    4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

    4/28/25 7:07:52 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/19/25 4:01:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/11/25 4:20:30 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nunn Jason Raleigh

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:58:46 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Fox Jennifer A.

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:38:35 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Oliveira Orlando

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:37:27 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    11/12/24 10:40:28 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    10/21/24 4:18:16 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/25/24 6:00:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

    WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

    4/7/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

    –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

    3/17/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care